The estimated Net Worth of James Canfield is at least $551 Tysiąc dollars as of 3 January 2005. James Canfield owns over 1,000 units of CTI BioPharma Corp stock worth over $510,549 and over the last 21 years James sold CTIC stock worth over $40,452.
James has made over 3 trades of the CTI BioPharma Corp stock since 2004, according to the Form 4 filled with the SEC. Most recently James sold 1,000 units of CTIC stock worth $8,020 on 3 January 2005.
The largest trade James's ever made was selling 3,334 units of CTI BioPharma Corp stock on 13 December 2004 worth over $25,172. On average, James trades about 667 units every 23 days since 2003. As of 3 January 2005 James still owns at least 56,166 units of CTI BioPharma Corp stock.
You can see the complete history of James Canfield stock trades at the bottom of the page.
James's mailing address filed with the SEC is 501 ELLIOT AVENUE WEST, SUITE 400, SEATTLE, WA, 98119.
Over the last 21 years, insiders at CTI BioPharma Corp have traded over $80,110,449 worth of CTI BioPharma Corp stock and bought 9,566,060 units worth $25,487,533 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Partners L P/Ilbiotechnolog... oraz Advisors Llc Orbi Med Capit.... On average, CTI BioPharma Corp executives and independent directors trade stock every 26 days with the average trade being worth of $1,223,687. The most recent stock trade was executed by Adam R Craig on 24 January 2023, trading 85,317 units of CTIC stock currently worth $71,666.
cti was founded on the belief that a coalition between unique scientific technology and its strong desire to “do right” by the patient could help us achieve our mission to acquire, develop and bring to market less toxic, more effective therapies to treat and cure cancer. we strive to do business better than other biopharmaceutical companies. better means a more collaborative, well-trained team environment willing to institute novel approaches to scientific discovery and business opportunities. a willingness to push the limits to achieve challenging goals is the essential attribute that sets cti employees apart.
CTI BioPharma Corp executives and other stock owners filed with the SEC include: